慢性自发性荨麻疹的临床评估体系

doi:10.35541/cjd.20210379

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (12): 1117-1121.doi: 10.35541/cjd.20210379

慢性自发性荨麻疹的临床评估体系

于淼^1，2 陈玉迪³ 刘擘¹ 宋晓婷¹ 廖双璐¹ 栾婷婷^1，2 赵作涛¹

¹北京大学第一医院皮肤性病科国家皮肤与免疫疾病临床医学研究中心皮肤病分子诊断北京市重点实验室 100034；²北京大学护理学院 100191；³北京医院皮肤科国家老年医学中心中国医学科学院老年医学研究院 100730

收稿日期:2021-05-12 修回日期:2021-08-06 发布日期:2021-12-01
通讯作者: 赵作涛 E-mail:zhaozuotaotao@163.com

Scoring systems for chronic spontaneous urticaria in clinical research and practice

Yu Miao^1,2, Chen Yudi³, Liu Bo¹, Song Xiaoting¹, Liao Shuanglu¹, Luan Tingting^1,2, Zhao Zuotao¹

¹Department of Dermatology and Venereology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China; ²Peking University School of Nursing, Beijing 100191, China; ³Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China

Received:2021-05-12 Revised:2021-08-06 Published:2021-12-01
Contact: Zhao Zuotao E-mail:zhaozuotaotao@163.com

摘要/Abstract

摘要： 【摘要】慢性自发性荨麻疹（CSU）严重影响患者的生活质量，目前尚缺乏敏感且检测方便的生物标志物来评估CSU的严重程度以及药物疗效。在CSU日常管理中选择具有良好信度、效度的患者报告结局评估工具格外重要，如荨麻疹活动度评分、荨麻疹疾病控制评分和慢性荨麻疹患者生活质量评分等。本文梳理了已有的CSU评估工具，分析其优点、局限性和在临床上的应用，旨在构建CSU临床评估体系，为制定个性化的治疗方案和疗效评估提供参考。

关键词: 荨麻疹, 生活质量, 健康状况指标, 疾病活动度, 疾病控制

Abstract: 【Abstract】 Chronic spontaneous urticaria （CSU） greatly affects the quality of life of patients. Currently, no sensitive and convenient biomarkers are available to assess the severity of CSU and efficacy of drug therapies. It is particularly important to apply patient-reported outcome assessment tools with good reliability and validity in daily management of CSU, such as urticaria activity score, urticaria control test and chronic urticaria quality of life questionnaire. This review outlines the existing CSU assessment tools, analyzes their strengths, limitations and clinical application, aiming to establish a CSU clinical scoring system, and to facilitate personalized treatment and efficacy evaluation.

Key words: Urticaria, Quality of life, Health status indicators, Disease activity, Disease control

于淼, 陈玉迪刘擘宋晓婷廖双璐栾婷婷, 赵作涛. 慢性自发性荨麻疹的临床评估体系[J]. 中华皮肤科杂志, 2021,54(12):1117-1121. doi:10.35541/cjd.20210379

Yu Miao, Chen Yudi, Liu Bo, Song Xiaoting, Liao Shuanglu, Luan Tingting, Zhao Zuotao. Scoring systems for chronic spontaneous urticaria in clinical research and practice[J]. Chinese Journal of Dermatology, 2021, 54(12): 1117-1121.doi:10.35541/cjd.20210379

参考文献 30

［1］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2018版）［J］. 中华皮肤科杂志, 2019,52（1）:1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001.
［2］	Zhong H, Song Z, Chen W, et al. Chronic urticaria in Chinese population: a hospital⁃based multicenter epidemiological study［J］. Allergy, 2014,69（3）:359⁃364. doi: 10.1111/all.12338.
［3］	Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real⁃world evidence from ASSURE⁃CSU［J］. Allergy, 2017,72（12）:2005⁃2016. doi: 10. 1111/all.13209.
［4］	Chu CY, Cho YT, Jiang JH, et al. Patients with chronic urticaria have a higher risk of psychiatric disorders: a population⁃based study［J］. Br J Dermatol, 2020,182（2）:335⁃341. doi: 10.1111/bjd.18240.
［5］	陈玉迪, 耿鹏, 赵嘉惠, 等. 慢性自发性荨麻疹:奥马珠单抗治疗作用机制与疗效评估［J］. 中华皮肤科杂志, 2019,52（9）:652⁃655. doi: 10.3760/cma.j.issn.0412⁃4030.2019.09.014.
［6］	Chen YD, Maurer M, Yu M, et al. Addition of omalizumab to antihistamine treatment in chronic urticaria: a real⁃world study in China［J］. Ann Allergy Asthma Immunol, 2020,125（2）:217⁃219. doi: 10.1016/j.anai.2020.04.026.
［7］	Chen Y, Yu M, Huang X, et al. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both［J］. World Allergy Organ J, 2021,14（1）:100501. doi: 10.1016/j.waojou.2020.100501.
［8］	Song XT, Chen YD, Yu M, et al. Omalizumab in children and adolescents with chronic urticaria: a 16⁃week real⁃world study［J］. Allergy, 2021,76（4）:1271⁃1273. doi: 10.1111/all.14686.
［9］	Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria［J］. Allergy, 2018,73（7）:1393⁃1414. doi: 10.1111/all.13397.
［10］	Hawro T, Ohanyan T, Schoepke N, et al. The urticaria activity score⁃validity, reliability, and responsiveness［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1185⁃1190.e1. doi: 10.1016/j.jaip.2017.10.001.
［11］	de Montjoye L, Darrigade AS, Giménez⁃Arnau A, et al. Correlations between disease activity, autoimmunity and biological parameters in patients with chronic spontaneous urticaria［J］. Eur Ann Allergy Clin Immunol, 2021,53（2）:55⁃66. doi: 10.23822/EurAnnACI.1764⁃1489.132.
［12］	谷锋, 沈云良. 血清IL⁃31表达水平与慢性自发性荨麻疹患者病变严重程度、瘙痒程度和生活质量的相关性研究［J］. 中华全科医学, 2019,17（9）:1527⁃1529. doi: 10.16766/j.cnki.issn. 1674⁃4152.000988.
［13］	Weller K, Groffik A, Magerl M, et al. Development, validation, and initial results of the angioedema activity score［J］. Allergy, 2013,68（9）:1185⁃1192. doi: 10.1111/all.12209.
［14］	Weller K, Groffik A, Church MK, et al. Development and validation of the urticaria control test: a patient⁃reported outcome instrument for assessing urticaria control［J］. J Allergy Clin Immunol, 2014,133（5）:1365⁃1372,1372.e1⁃6. doi: 10.1016/ j.jaci.2013.12.1076.
［15］	于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证［J］. 中华皮肤科杂志, 2020,53（7）:533⁃538. doi: 10. 35541/cjd.20191190.
［16］	Kulthanan K, Chularojanamontri L, Tuchinda P, et al. Validity, reliability and interpretability of the Thai version of the urticaria control test （UCT）［J］. Health Qual Life Outcomes, 2016,14:61. doi: 10.1186/s12955⁃016⁃0466⁃y.
［17］	Weller K, Donoso T, Magerl M, et al. Validation of the angioedema control test （AECT）⁃a patient⁃reported outcome instrument for assessing angioedema control［J］. J Allergy Clin Immunol Pract, 2020,8（6）:2050⁃2057.e4. doi: 10.1016/j.jaip. 2020.02.038.
［18］	朱海军, 庞雅男, 李芳芳, 等. 慢性荨麻疹患者生活质量评估及影响因素分析［J］. 中国中西医结合皮肤性病学杂志, 2020,19（6）:536⁃539.
［19］	Finlay AY, Khan GK. Dermatology Life Quality Index （DLQI）⁃⁃a simple practical measure for routine clinical use［J］. Clin Exp Dermatol, 1994,19（3）:210⁃216. doi: 10.1111/j.1365⁃2230.1994.tb01167.x.
［20］	刘江波, 司爱丽, 邓蕾, 等. 慢性荨麻疹患者生活质量评估及皮肤病生活质量指数的因子分析和信度分析［J］. 中华皮肤科杂志, 2011,44（1）:47⁃49. doi: 10.3760/cma.j.issn.0412⁃4030. 2011.01.017.
［21］	Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index （DLQI）: further data［J］. Dermatology, 2015,230（1）:27⁃33. doi: 10.1159/000365390.
［22］	Balp MM, Khalil S, Tian H, et al. Burden of chronic urticaria relative to psoriasis in five European countries［J］. J Eur Acad Dermatol Venereol, 2018,32（2）:282⁃290. doi: 10.1111/jdv.14584.
［23］	Serra E, Campo C, Novák Z, et al. Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study［J］. J Dermatolog Treat, 2020,31（3）:270⁃278. doi: 10.1080/09546634. 2019.1590522.
［24］	Baiardini I, Braido F, Bindslev⁃Jensen C, et al. Recommendations for assessing patient⁃reported outcomes and health⁃related quality of life in patients with urticaria: a GA（2） LEN taskforce position paper［J］. Allergy, 2011,66（7）:840⁃844. doi: 10.1111/j.1398⁃9995.2011.02580.x.
［25］	Schut C, Dalgard FJ, Halvorsen JA, et al. Occurrence, chronicity and intensity of itch in a clinical consecutive sample of patients with skin diseases: a multi⁃centre study in 13 European countries［J］. Acta Derm Venereol, 2019,99（2）:146⁃151. doi: 10.2340/00015555⁃3040.
［26］	Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire （CU⁃QoL）［J］. Allergy, 2005,60（8）:1073⁃1078. doi: 10.1111/j.1398⁃9995.2005.00833.x.
［27］	于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷（CU⁃Q2oL）信效度验证［J］. 中华皮肤科杂志, 2020,53（12）:992⁃997. doi: 10.35541/cjd.20200091.
［28］	Baiardini I, Fasola S, Maurer M, et al. Minimal important difference of the chronic urticaria quality of life questionnaire （CU⁃Q2oL）［J］. Allergy, 2019,74（12）:2542⁃2544. doi: 10.1111/all.13939.
［29］	Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire［J］. Allergy, 2012,67（10）:1289⁃1298. doi: 10.1111/all.12007.
［30］	Weller K, Magerl M, Peveling⁃Oberhag A, et al. The angioedema quality of life questionnaire （AE⁃QoL） ⁃ assessment of sensitivity to change and minimal clinically important difference［J］. Allergy, 2016,71（8）:1203⁃1209. doi: 10.1111/all.12900.

[1]	刘倩李国宏陈炳为. 非黑素瘤皮肤癌患者生活质量及影响因素调查[J]. 中华皮肤科杂志, 2021, 54(9): 819-821.
[2]	张宇高迎霞顾宁琰朱虹陈京京胡清洁周敏段媛媛姚煦. 奥马珠单抗对慢性自发性荨麻疹患者的临床疗效和安全性分析[J]. 中华皮肤科杂志, 2021, 54(7): 582-585.
[3]	梁高澎宋志强. 免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展[J]. 中华皮肤科杂志, 2021, 54(6): 553-556.
[4]	邓青刘芳芬施为谢红付李吉黄莹雪. 长沙地区玫瑰痤疮患者的支付意愿调查及影响因素分析[J]. 中华皮肤科杂志, 2021, 54(4): 352-355.
[5]	闫慧敏杜笑孟令贺翁立硕曾三武. 基于16S rRNA基因测序的慢性自发性荨麻疹患者肠道菌群差异研究[J]. 中华皮肤科杂志, 2021, 54(12): 1071-1076.
[6]	宋晓婷刘擘陈玉迪于淼, 廖双璐栾婷婷, 赵作涛. 奥马珠单抗治疗慢性自发性荨麻疹的疗效及安全性分析[J]. 中华皮肤科杂志, 2021, 54(12): 1063-1070.
[7]	赵作涛. 慢性荨麻疹诊治：现状与展望[J]. 中华皮肤科杂志, 2021, 54(12): 1105-1109.
[8]	宋晓婷刘擘陈玉迪于淼廖双璐栾婷婷赵作涛. 奥马珠单抗治疗27例人工荨麻疹回顾分析[J]. 中华皮肤科杂志, 2021, 54(12): 1092-1096.
[9]	陈奇权宋志强. 慢性可诱导性荨麻疹的治疗进展[J]. 中华皮肤科杂志, 2021, 54(12): 1110-1113.
[10]	中华医学会皮肤性病学分会荨麻疹研究中心. 抗IgE疗法——奥马珠单抗治疗慢性荨麻疹专家共识[J]. 中华皮肤科杂志, 2021, 54(12): 1057-1062.
[11]	刘鑫刘念陈宏翔. 接触性荨麻疹诊治进展[J]. 中华皮肤科杂志, 2021, 54(12): 1114-1117.
[12]	高萌, 姜祎群. 新型冠状病毒肺炎伴发的皮肤表现[J]. 中华皮肤科杂志, 2021, 0(1): 20200509-e20200509.
[13]	焦晴晴, 张晓艳, 季江. 慢性自发性荨麻疹活动度相关生物学指标的研究进展[J]. 中华皮肤科杂志, 2021, 0(1): 20201158-e20201158.
[14]	于淼张晶陈玉迪刘擘宋晓婷刘晶张雪赵作涛. 中文版瘙痒患者生活质量问卷信效度及敏感性验证[J]. 中华皮肤科杂志, 2020, 53(9): 698-703.
[15]	于淼陈玉迪刘擘宋晓婷赵作涛. 中文版荨麻疹控制评分量表及信效度验证[J]. 中华皮肤科杂志, 2020, 53(7): 533-538.

慢性自发性荨麻疹的临床评估体系

Scoring systems for chronic spontaneous urticaria in clinical research and practice

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

Metrics

本文评价

推荐阅读 10